
DISEASE MANAGEMENT
Eliglustat
What is eliglustat?
Eliglustat is an oral substrate reduction therapy for Gaucher disease.
INTRODUCING
The introduction of enzyme replacement therapy and substrate reduction therapy has enhanced the management of Gaucher disease.
Miglustat is a substrate reduction therapy indicated for the oral treatment of patients with Gaucher disease.1 The mechanism of action of miglustat is presented in Figure 1. For further information on miglustat, please consult your local prescribing information.
Figure 1.
Mechanism of action of miglustat1,2
C-ANPROM/INT//7568; Date of preparation: September 2020
DISEASE MANAGEMENT
What is eliglustat?
Eliglustat is an oral substrate reduction therapy for Gaucher disease.
DISEASE MANAGEMENT
What substrate reduction therapies are available for Gaucher disease?
Two oral substrate reduction therapies are available for Gaucher disease: miglustat and eliglustat.
DISEASE MANAGEMENT
What enzyme replacement therapies are available for Gaucher disease?
Three long-term enzyme replacement therapies are available for patients with Gaucher disease: imiglucerase, velaglucerase alfa and taliglucerase alfa.
Register
Registration gives the benefit of site update emails and additional information on new education materials and events